The panelists discussed if they believed that the oral parity laws—where patients would pay the same amount for an oral drug as an IV-administered one—would receive a political push for implementation from the federal government.
John L. Fox, MD, MHA, explained that when the laws were first introduced there was little cost sharing on the medical benefit and higher cost sharing on the pharmacy benefit. Things have changed so that, now, over 60% of patients on the commercial side of the Priority Health plan have significant deductibles and coinsurance after that. There is less cost sharing on the pharmacy benefit for an oral cancer drug than on the medical benefit but an unintended consequence of this is that oral prices may increase for patients.
Ted Okon said he did not personally believe that there is a chance that the federal government will get involved, and that it will be up to the states. In some cases this state-by state regulation is a good thing, but there are some instances that there will be unintended consequences as Dr Fox indicated, Okon agreed. There are patients who will end up paying more for oral drugs than if they had injectables, and part of this problem is a lack of discussion with the patients. Patient groups want to hear about the value propositions, they want more advocacy and involvement, Okon said.
Okon described the studies that Community Oncology Alliance is performing on cost drivers and said that the issues are not just restricted to the drug industry but also include community oncology and academic institutions. “…I think it’s a holistic view that we need to take here in terms of where the care is delivered, the site of care and also all of the other services. A lot of people are a part of this problem and a lot of people have to be part of the solution,” Okon finished.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More